# US 2023/0265161 A1 · Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265161 A1
- Document ID: US20230265161A1
- Status: Published application
- Kind: A1
- Application number: 17/942,695
- Filed: 2022-09-12
- Published: 2023-08-24
- Earliest claimed: 2016-10-05
- Assignees: Acceleron Pharma Inc.
- Applicants: Acceleron Pharma Inc.
- Inventors: Ravindra Kumar; Asya Grinberg; Dianne S. Sako; Roselyne Castonguay
- Web page: https://patentgrep.com/patent/US20230265161A1

## CPC

- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- C07K 14/71: for growth factors; for growth regulators
- A61P 7/06: Antianaemics
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolic parameters, and disorders associated with these tissues, cellular networks, and endocrine systems.

## Claims

### Claim at position 1

1-168. (canceled)

### Claim 169

A recombinant heteromultimer comprising an ALK7-Fc fusion protein and an ActRIIB-Fc fusion protein,
(a) wherein the ALK7-Fc fusion protein comprises:
(1) an ALK7 domain comprising an amino acid sequence that is at least 90% identical to amino acids 21-113 of SEQ ID NO: 38, and
(2) an Fc domain; and
(b) wherein the ActRIIB-Fc fusion protein comprises:
(1) an ActRIIB domain comprising an amino acid sequence that is at least 90% identical to amino acids 29-109 of SEQ ID NO: 1, and
(2) an Fc domain.

### Claim 170 (depends on 169)

The heteromultimer of claim 169, wherein the ALK7-Fc fusion protein and ActRIIB fusion protein Fc domain is an IgG1 Fc domain comprising an amino acid sequence that is at least 90%, identical to the amino acid sequence of SEQ ID NO: 3100.

### Claim 171 (depends on 170)

The heteromultimer of claim 170, wherein the ALK7-Fc fusion protein IgG1 Fc domain comprises a cysteine substitution at the position corresponding to Y127 of SEQ ID NO: 3100 (Y127C), a serine substitution at the position corresponding to T144 of SEQ ID NO: 3100 (T144S), an alanine substitution at the position corresponding to L146 of SEQ ID NO: 3100 (L146A), and a valine substitution at the position corresponding to Y185 of SEQ ID NO: 3100 (Y185V).

### Claim 172 (depends on 170)

The heteromultimer of claim 170, wherein the ALK7-Fc fusion protein comprises a cysteine substitution at the position corresponding to S132 of SEQ ID NO: 3100 (S132C) and a tryptophan substitution at the position corresponding to T144 of SEQ ID NO: 3100 (T144W).

### Claim 173 (depends on 170)

The heteromultimer of claim 170, wherein the ActRIIB-Fc fusion protein IgG1 Fc domain comprises a cysteine substitution at the position corresponding to Y127 of SEQ ID NO: 3100 (Y127C), a serine substitution at the position corresponding to T144 of SEQ ID NO: 3100 (T144S), an alanine substitution at the position corresponding to L146 of SEQ ID NO: 3100 (L146A), and a valine substitution at the position corresponding to Y185 of SEQ ID NO: 3100 (Y185V).

### Claim 174 (depends on 170)

The heteromultimer of claim 170, wherein the ActRIIB-Fc fusion protein IgG1 Fc domain comprises a cysteine substitution at the position corresponding to S132 of SEQ ID NO: 3100 (S132C) and a tryptophan substitution at the position corresponding to T144 of SEQ ID NO: 3100.

### Claim 175 (depends on 169)

The heteromultimer of claim 169, wherein:
a) the ActRIIB-Fc fusion protein comprises one or more amino acid modifications that increase the pI of the ActRIIB-Fc fusion protein; and
b) the ALK7-Fc fusion protein comprises one or more amino acid modifications that decrease the pI of the ALK7-Fc fusion protein.

### Claim 176 (depends on 169)

The heteromultimer of claim 169, wherein the ALK7-Fc fusion protein comprises an ALK7 domain comprising an amino acid sequence that is at least 90% identical to an amino acid sequence selected from:
a) a polypeptide that:
i) begins at any one of amino acids 21-28 of SEQ ID NO: 305 or 309, and
ii) ends at any one of amino acids 92-113 of SEQ ID NO: 305 or 309;
b) amino acids 28-92 of SEQ ID NOs: 38, 305, or 309;
c) amino acids 21-113 of SEQ ID NOs: 305 or 309; and
d) amino acid sequence of any one of SEQ ID Nos: 38, 39, 301, 302, 305, 306, 309, 310, 313, 112, 114, 405, and 406.

### Claim 177 (depends on 169)

The heteromultimer of claim 169, wherein the ActRIIB-Fc fusion protein comprises an ActRIIB domain comprising an amino acid sequence that is at least 90% identical to an amino acid sequence selected from:
a) a polypeptide that:
i) begins at any one of amino acids of 20-29 SEQ ID NO: 1, and
ii) ends at any one of amino acids 109-134 of SEQ ID NO: 1;
b) 20-134 of SEQ ID NO: 1;
d) 25-131 of SEQ ID NO: 1; and
e) amino acid sequence of any one of SEQ ID Nos: 1, 2, 3, 4, 5, 6, 100, 102, 401, and 402.

### Claim 178 (depends on 169)

The heteromultimer of claim 169, wherein the ALK7-Fc fusion protein further comprises a linker domain positioned between the ALK7 domain and the Fc domain; and wherein the ActRIIB-Fc fusion protein further comprises a linker domain positioned between the ActRIIB domain and the Fc domain.

### Claim 179 (depends on 178)

The heteromultimer of claim 178, wherein the linker domain is selected from: TGGG (SEQ ID NO: 62), TGGGG (SEQ ID NO: 60), SGGGG (SEQ ID NO: 61), GGGGS, GGG (SEQ ID NO: 58), GGGG (SEQ ID NO: 59), and SGGG (SEQ ID NO: 18).

### Claim 180 (depends on 169)

The heteromultimer of claim 169, wherein the heteromultimer is a heterodimer.

### Claim 181 (depends on 169)

A pharmaceutical preparation comprising the heteromultimer of claim 169, and a pharmaceutically acceptable carrier.
